US 12,076,089 B2
Denervation therapy
Paul J. Coates, Corte Madera, CA (US); and Douglas A. Hettrick, Andover, MN (US)
Assigned to Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed by Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed on Jul. 25, 2022, as Appl. No. 17/814,757.
Application 17/814,757 is a continuation of application No. 17/025,810, filed on Sep. 18, 2020, granted, now 11,419,681.
Application 17/025,810 is a continuation of application No. 15/965,675, filed on Apr. 27, 2018, granted, now 10,786,306, issued on Sep. 29, 2020.
Claims priority of provisional application 62/621,351, filed on Jan. 24, 2018.
Prior Publication US 2022/0354581 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 34/10 (2016.01); A61B 5/00 (2006.01); A61B 5/0536 (2021.01); A61B 5/055 (2006.01); A61B 5/20 (2006.01); A61B 6/03 (2006.01); A61B 6/46 (2024.01); A61B 6/50 (2024.01); A61B 8/08 (2006.01); A61B 18/00 (2006.01); A61B 18/06 (2006.01); A61B 18/14 (2006.01); A61B 18/24 (2006.01); A61B 34/00 (2016.01); A61B 90/00 (2016.01); G16H 50/50 (2018.01); A61B 6/00 (2006.01); A61B 6/12 (2006.01); A61B 8/00 (2006.01); A61B 17/32 (2006.01); A61B 18/02 (2006.01); A61B 18/18 (2006.01); A61B 34/20 (2016.01)
CPC A61B 34/10 (2016.02) [A61B 5/0066 (2013.01); A61B 5/0536 (2013.01); A61B 5/055 (2013.01); A61B 5/201 (2013.01); A61B 5/40 (2013.01); A61B 5/4041 (2013.01); A61B 5/4047 (2013.01); A61B 5/4052 (2013.01); A61B 5/407 (2013.01); A61B 6/032 (2013.01); A61B 6/037 (2013.01); A61B 6/461 (2013.01); A61B 6/506 (2013.01); A61B 8/0891 (2013.01); A61B 18/06 (2013.01); A61B 18/1492 (2013.01); A61B 18/24 (2013.01); A61B 34/25 (2016.02); A61B 90/37 (2016.02); G16H 50/50 (2018.01); A61B 6/00 (2013.01); A61B 6/12 (2013.01); A61B 6/465 (2013.01); A61B 8/0841 (2013.01); A61B 8/085 (2013.01); A61B 8/461 (2013.01); A61B 2017/320069 (2017.08); A61B 2018/00351 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/1435 (2013.01); A61B 2018/1861 (2013.01); A61B 2034/104 (2016.02); A61B 2034/107 (2016.02); A61B 34/20 (2016.02); A61B 2090/3735 (2016.02); A61B 2090/374 (2016.02); A61B 2090/376 (2016.02); A61B 2090/3762 (2016.02); A61B 2090/378 (2016.02); A61B 2090/3954 (2016.02); A61B 2090/3958 (2016.02); A61B 2090/3966 (2016.02)] 21 Claims
OG exemplary drawing
 
1. A method comprising:
determining, by processing circuitry and based on one or more tissue characteristics of a region of a patient, the region comprising a target nerve and a blood vessel of a patient, a response state associated with each denervation stimulus of a plurality of denervation stimuli delivered to the region by a therapy delivery device disposed within the blood vessel;
determining, by the processing circuitry and for each denervation stimulus of the plurality of denervation stimuli, whether a viability of the target nerve is below a threshold based on the respective response state, wherein the viability of the target nerve being below the threshold is indicative of a reduction in function of the target nerve; and
selecting, by the processing circuitry, a denervation stimulus from the plurality of denervation stimuli based on the determined viability of the target nerve.